Apollo Proton Cancer Centre’s Post

What proportion of prostate cancer (mCRPC) patients are eligible for PSMA-directed radioligand therapy (RLT)? Depends on what imaging criteria is applied. The pivotal phase 3 VISION trial utilized a 68Ga-PSMA11 PET/CT scan to select appropriate patients. -> 87% of patients were eligible for therapy. The phase 2 TheraP trial utilized dual PSMA11 and FDG PET scans. -> 72% of patients were eligible for therapy. A recent study published in The Journal of Nuclear Medicine - JNM investigated a triple PET tracer strategy: PSMA11, FDG, and DOTATATE. -> 53% of patients were eligible for therapy. Two separate retrospective studies comparing different imaging-based eligibility criteria concluded: 1)    “Performing PSMA PET/CT including a contrast-enhanced CT as proposed in the VISION trial might be sufficient for treatment eligibility of end-stage prostate cancer patients” 2)    “PSMA PET/CT alone might be sufficient for 177Lu-PSMA therapy eligibility assessment” References in comments below. #psma #rlt #theranostics #nuclearmedicine #prostatecancer

Earlier this fall, I presented groundbreaking findings from the PARTIQoL trial, a first-of-its-kind phase III clinical trial comparing intensity modulated radiation therapy (IMRT) and proton beam therapy for prostate cancer. Thank you Mass General Brigham for featuring the PARTIQoL trial! Key findings from the PARTIQoL trial. 🔹 Equally Effective Treatments: Both IMRT and proton therapy achieved high tumor control rates with no differences in patient-reported quality of life. 🔹 Diverse Patient Cohort: The trial enrolled 450 patients from 29 centers, with significant representation from minority populations—20% non-white, including 13% Black or African American. 🔹 Patient-Centric Focus: Participants self-reported on bowel, urinary, and sexual functions, prioritizing quality of life in treatment decisions. 🔹 Innovative Design: The study applied rigorous methods typically reserved for drug trials, ensuring robust and relevant findings for radiation technology. I want to emphasize again that both treatment options are very safe and effective, offering patients more choices and greater peace of mind. Mass General Brigham American Society for Radiation Oncology (ASTRO) #ProstateCancer #RadiationOncology #MGH #CancerResearch Photo by © ASTRO/Scott Morgan 2024

Didn't catch our posters at #AACR2024? 🤔 We presented a novel approach using patient-derived organoids and engineered T cell co-cultures for T cell drug development. Click on the link below to download the poster and learn: ✨How we developed an organoid-based co-culture system with engineered T cells ✨How we established a preclinical basket screen consisting of breast, colorectal, lung, head and neck, ovarian, and pancreatic organoids to help with our client's research needs ✨How organoid technology helped our client in making clinically informed decisions on selection of disease indication for their IO compound in solid tumors #Tcells #CART #engineeredTcells #organoids #TME #patientinthelab #cancer #immunotherapy

ASCO 2024 Highlight: Dr Willem Lybaert, medical oncologist from VITAZ Sint Niklaas & University Hospital Antwerp, presents a comprehensive summary of the oral abstract session on gastroesophageal, pancreatic and hepatobiliary tumours. Key highlights include: ECOG-ACRIN trial, RENAISSANCE trial and ARMANI study for oesophageal adenocarcinoma and gastro-oesophageal junction tumours. GIANT trial, PASS-01 phase 2 study, and NRG Oncology/RTOG 0848 study in pancreatic cancer. CheckMate 9DW study focusing on first-line treatment for HCC with nivolumab plus ipilimumab versus sorafenib or lenvatinib. Discover these updates. For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #GICancer #OncologyInnovation

New!📌 Validation of a multiomic model of #plasmaextracellularvesicle PD-L1 and radiomics for prediction of response to #immunotherapy in NSCLC ----------------------------- Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. Here Christian Rolfo, MD, PhD, MBA,Dr.h.c. et al. showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response to ICIs. Look here⤵️ https://lnkd.in/dbEeYh6y #LungCancer #Immunecheckpointinhibitor #LiquidBiopsy IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

NEW from #ESMO2024 | NIAGARA: perioperative #durvalumab with neoadjuvant #chemotherapy in MIBC 🎥 🇪🇸 Guru Sonpavde, MD, Adventhealth Cancer Institute, gives an overview of the Phase III NIAGARA trial (NCT03732677), which assessed neoadjuvant #durvalumab plus #chemotherapy followed by radical #cystectomy and adjuvant #durvalumab in #cisplatin-eligible patients with muscle-invasive #bladdercancer (MIBC) 🔦 🌟 A statistically significant improvement in event-free survival and overall survival were reported, highlighting the practice-changing nature of the trial 🌟 Learn more 👉 https://lnkd.in/eqK-UQup #VJOncology #Oncologynews

Study aimed to reassess the comparative effectiveness of proton beam therapy (PBT) versus intensity-modulated radiation therapy (IMRT) for localized prostate cancer, focusing on gastrointestinal (GI) and genitourinary (GU) toxicity. Analyzing data from the SEER-Medicare linked database, patients diagnosed between 2010 and 2017 were matched based on clinical and sociodemographic characteristics. Results indicated no statistically significant differences in GI or GU toxicity between PBT and IMRT at 6, 12, and 24 months post-treatment. The findings suggest that both modalities exhibit comparable toxicity profiles in this context, emphasizing the need for ongoing assessment to guide treatment decisions effectively. Source:JCO (ASCO) https://lnkd.in/dG-yx8p9 James Yu David DeStephano David Horowitz Pamela Soulos Cary Gross Alizée Camps--Maléa Icro Meattini Henning Willers, MD, FASTRO Prof. Dr. Axel S. Merseburger Petros Grivas

A new combination of immunotherapy and chemotherapy has shown promising results in treating metastatic pancreatic cancer, according to a study by the Val d’Hebron Oncology Institute. The research revealed that combining the antibody CD40 IgG1 with first-line chemotherapy led to significant clinical benefits in patients with advanced pancreatic ductal adenocarcinoma. These findings offer hope for developing more effective treatment strategies for patients facing this aggressive form of cancer. Hashtags: #Immunotherapy #Chemotherapy #PancreaticCancer #CancerResearch #Biohacking Read more here: https://lnkd.in/ekPwnrQx BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

Targeting the Hallmarks of Cancer has been the long term strategy for beating cancer. Understanding the components of how metastases form is a topic that I took great interest in during my degree. Blocking angiogenesis is a key strategy in cancer treatment. Recent findings show how innovative drugs are cutting off the blood supply to tumors, leading to more targeted and effective therapies. #AngiogenesisInhibition #CancerTherapies" Jayson, G.C., et al. (2016). Antiangiogenic therapy in oncology: Current status and future directions. The Lancet, 388(10043), 518-529. Folkman, J. (2007). Angiogenesis: An organizing principle for drug discovery? Nature Reviews Drug Discovery, 6(4), 273-286. doi:10.1038/nrd2115 Kerbel, R.S. (2008). Tumor angiogenesis. The New England Journal of Medicine, 358(19), 2039-2049. doi:10.1056/NEJMra0706596 Gerriets V, Kasi A. Bevacizumab. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: